2 results found
This detailed analysis of the alarming Pennsylvania measles outbreak highlights four tragic fatalities, including an 18-year-old from severe neurological complications. It underscores critical public health challenges, including declining vaccination rates and federal data reporting controversies, while emphasizing the urgent need for reliable information and widespread vaccination.
Eli Lilly is set to acquire Seattle-area biotech Curevo Vaccine for up to $1.5 billion to bolster its infectious disease portfolio. The deal centers on Curevo's Phase 3-ready shingles vaccine candidate, amezosvatein, which demonstrated a more than 50% reduction in side effects during Phase 2 studies, aiming to boost vaccination rates among older adults.
